ISPOR ANNOUNCES NEW 2017 HEALTH ECONOMICS AND OUTCOMES RESEARCH TRAINING PROGRAMS

Published Dec 5, 2016
Princeton, NJ—December 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced  its upcoming health economics and outcomes research (HEOR) in-person training programs scheduled for early 2017.   ISPOR Health Technology Assessment (HTA) Training Program 20-23 February 2017 | Bogotá, Colombia The ISPOR Health Technology Assessment (HTA) Training Program is designed “HTA users and doers” in government in addition to public and private payers, industry, health plans, academia, and patient group representatives interested in learning how to conduct various aspects of HTA with an emphasis on clinical and economic evaluation. Program faculty includes Finn Børlum Kristensen, MD, PhD, Manuel Espinoza, MD, MSc, PhD, and Aurelio Mejía, MSc, BSc. Additional information on the training can be found here. Essential Elements of Pricing Training Program March 9-10, 2017 | Philadelphia, PA, USA The Essential Elements of Pricing Training Program educates attendees on the context, rules, and processes behind pharmaceutical pricing in addition to an overview of the tradeoffs, commonalities, and differences between markets and disease areas. Faculty for the program includes, Jack Mycka and Renato Dellamano. Additional information can be found here. Introduction to Health Economics and Outcomes Research Training Program April 6-7, 2017 | San Francisco, CA, USA The Introduction to Health Economics and Outcomes Research (HEOR): Principles and Practice in Health Care Decision Making Training Program. Provides participants with the essential skills required to perform and critique health care economic studies and models to determine cost-effective medications, devices, and interventions. This training will be led by Lorne E. Basskin, PharmD. Program information can be found here. Additional information on ISPOR In-Person Training Programs can be found here and details on the ISPOR HTA Training Program can be found here.

###

 

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×